Conventional imaging is suboptimal at evaluating disease status in renal cell carcinoma (RCC) because of poor sensitivity. Furthermore, there is an unmet need for the treatment of metastatic RCC, both ...
Background: Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that has demonstrated superior efficacy over interferon (IFN)-α in a phase III trial in first-line, metastatic renal ...
Specificity of radiographic lymphadenopathy for lymph node metastasis in renal cell carcnioma. This is an ASCO Meeting Abstract from the 2015 Genitourinary Cancers Symposium. This abstract does not ...
In a recent study published in Cancers, researchers explored the association between the human microbiome and improved renal cell carcinoma (RCC) outcomes. Study: A New Treatment Landscape for RCC: ...
Clear cell renal cell carcinoma (RCC) is the most common histological subtype of malignant kidney tumors. Clinically, clear cell RCC cannot be distinguished from other histological RCC classes based ...
Emerging treatments for renal cell carcinoma (RCC), including kinase inhibitors, checkpoint inhibitors, and combinations of these new agents, are improving outcomes for patients A need for biomarkers ...
Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline BRCA1/2-Mutated Breast Cancers in the High-Risk, Early-Stage Setting Targeted tyrosine kinase inhibitors (TKIs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results